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Abstract
Background: Epilepsy is a common neurological disorder, with over 80 % of cases found in low- and middle-income
countries (LMICs). Studies from high-income countries find a significant economic burden associated with epilepsy, yet
few studies from LMICs, where out-of-pocket costs for general healthcare can be substantial, have assessed
out-of-pocket costs and health care utilization for outpatient epilepsy care.
Methods: Within an established health and socio-demographic surveillance system in rural South Africa, a
questionnaire to assess self-reported health care utilization and time spent traveling to and waiting to be seen at
health facilities was administered to 250 individuals, previously diagnosed with active convulsive epilepsy. Epilepsy
patients’ out-of-pocket, medical and non-medical costs and frequency of outpatient care visits during the previous
12-months were determined.
Results: Within the last year, 132 (53 %) individuals reported consulting at a clinic, 162 (65 %) at a hospital and 34
(14 %) with traditional healers for epilepsy care. Sixty-seven percent of individuals reported previously consulting with
both biomedical caregivers and traditional healers. Direct outpatient, median costs per visit varied significantly
(p < 0.001) between hospital (2010 International dollar ($) 9.08; IQR: $6.41-$12.83) and clinic consultations ($1.74;
IQR: $0-$5.58). Traditional healer fees per visit were found to cost $52.36 (IQR: $34.90-$87.26) per visit. Average
annual outpatient, clinic and hospital out-of-pocket costs totaled $58.41. Traveling to and from and waiting to
be seen by the caregiver at the hospital took significantly longer than at the clinic.
Conclusions: Rural South Africans with epilepsy consult with both biomedical caregivers and traditional healers
for both epilepsy and non-epilepsy care. Traditional healers were the most expensive mode of care, though utilized
less often. While higher out-of-pocket costs were incurred at hospital visits, more people with ACE visited hospitals
than clinics for epilepsy care. Promoting increased use and effective care at clinics and reducing travel and waiting
times could substantially reduce the out-of-pocket costs of outpatient epilepsy care.
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Background
Epilepsy is a common neurological disorder with 80 % of
all cases found in low- and middle-income countries
(LMICs) [1]. Ten million people live with epilepsy on
the African continent alone [2]. Studies from LMICs
have quantified the epidemiological burden of epilepsy -
consistently showing higher incidence [3] and mortality
[4] associated with epilepsy. However, few population-
based studies have explored the utilization and cost of
health care due to epilepsy in these countries, with no
known studies from South Africa.
Due to its chronic, stigmatizing, and often debilitating
nature, epilepsy carries significant economic costs in terms
of both medical treatment and lost economic productivity
[5]. Studies have found costs to vary by seizure type and
frequency, temporal stage of the disorder, diagnostic and
treatment tools available, and the frequency and type of
health care services utilized by people with epilepsy [6]. A
review of 22 cost-of-illness studies on epilepsy from both
low- and middle-income and high-income countries found
mean annual direct costs (costs related to seeking and re-
ceiving care for epilepsy) to range from 2006 International
dollar ($) 40 to $4768, with costs substantially lower in
LMICs, ranging from $40 to $384 [7]. Anti-epileptic drugs
(AEDs) and hospital admissions are major drivers of direct
costs associated with epilepsy treatment [7].
The few African studies that exist find that costs due
to epilepsy can be substantial, with the majority of costs
due to AEDs [7]. A population-based Burundian study
found people with epilepsy to have significantly higher
annual health care costs than those without any neuro-
logical condition, with those taking AEDs experiencing a
440 % increase [8]. A Nigerian study, exploring the cost
of pediatric epilepsy at a tertiary health facility, found that
more than half of all families with a household member
with epilepsy spent more than 20 % of the family’s total
income on their care [9].
Health care utilization
Health care utilization is an important component of
both costs and adherence, with the relationship between
these factors often bidirectional and complex [10, 11].
Studies from high-income countries show that people
with epilepsy utilize health care more often than people
without epilepsy due to repeat drug prescriptions [12]
and increased emergency room usage [13].
Existing studies in LMICs find a large epilepsy treat-
ment gap - defined as those not on treatment or on in-
adequate treatment [14]. An analysis of 27 studies from
LMICs found an overall treatment gap of 56 % [15]. This
suggests that people do not utilize (or receive) the health
care they need. Cost of treatment, unavailability of
drugs, and inadequate healthcare manpower all contrib-
uted significantly to the observed treatment gap [15]. By
understanding costs and health care utilization for people
with epilepsy, interventions to remove barriers and im-
prove access to care can be developed. In South Africa,
where standard AEDs are provided free of charge, under-
standing drivers of out-of-pocket costs and time spent
seeking health care may provide insights on how to reduce
the treatment gap.
In the current study, we determined the health care
utilization of people with active convulsive epilepsy, esti-
mated the time spent seeking outpatient treatment and
calculated direct out-of-pocket costs in a rural South
African context. This is the first study of its kind from
South Africa.
Methods
Study area and population
The Agincourt Health and Socio-Demographic Surveillance
System (HDSS) site, located in the Agincourt health
sub-district of the Bushbuckridge municipality, comprises
420 km2 of semi-arid, rural scrubland, 500 km northeast
of Johannesburg, South Africa in Mpumalanga Province
adjacent to Mozambique. Established as a research site in
1992, the Agincourt HDSS (http://www.agincourt.co.za)
aims to inform health and development policy through
evidence-based research and has generated socio-
demographic data since its inception through annual
census updates that capture vital statistics, including
births, deaths, and in- and out-migrations.
The 2011 mid-year population was roughly 90,000 in-
dividuals in 16,000 households and 27 research villages
[16]. The majority of the population speaks Xitsonga
with one-third of the population of Mozambican origin.
Unemployment remains high in Agincourt with 36 %
of the adult population (older than 18 years old) unemployed
and currently looking for work [17]. The socio-economic
status of the site has improved over the last 20 years,
though as of 2011, 20 % of the population was still liv-
ing in extreme poverty (personal communication, Mark
Collinson). Government grants provide much needed
financial support, with the majority of Agincourt house-
holds receiving at least one (personal communication,
Mark Collinson).
Within the Agincourt site, a network of six, govern-
ment primary health care (PHC) clinics offers free basic,
outpatient health services during regular business hours.
These services include mother and child care, including
immunizations, family planning, testing and treatment
for sexually transmitted infections, including HIV, minor
trauma and routine care for those with chronic condi-
tions, including epilepsy [18].
The six clinics refer patients to one larger government
community health centre within the site. The health
centre provides PHC services as well as 24-h acute care
and facilities for 48-h patient observation [18]. Nurses
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run both clinics and health centres, though doctors do
visit clinics and health centres.
A public-private partnership community health centre
within the site provides HIV, tuberculosis and other
chronic disease care and treatment. Clinicians staff this
facility.
Referrals from primary health care facilities in the
Agincourt research site are made to three government
hospitals located 25-55 km from the site. Clinicians at
the hospitals primarily diagnose epilepsy and initiate
therapy before referring patients to the clinics or health
centre for monthly AED collection [19]. People with epi-
lepsy are expected to return to the hospital at 6-month
intervals for review of seizure frequency and treatment.
Case definition and case ascertainment
A 2008 cross-sectional survey sought to identify all indi-
viduals with active convulsive epilepsy (ACE) living within
the Agincourt HDSS [20]. ACE was defined as having ≥2
unprovoked convulsive seizures occurring more than 24 h
apart, with at least one seizure occurring in the year pre-
ceding the study or currently taking AEDs for epilepsy
[20]. After undergoing a clinical history and neurological
exam, 311 individuals living within the Agincourt HDSS
were diagnosed with ACE by the study neurologist (CRN),
yielding an adjusted ACE prevalence of 7.0 per 1000 indi-
viduals [20].
Data collection
Between September 2010 and January 2011, trained
fieldworkers attempted to visit each individual diagnosed
with ACE and/or his/her caregiver. If consent was given,
the respondent was asked questions regarding health care
utilization over the previous 12-months. Questions on out-
of-pocket costs associated with utilization of outpatient
care for the treatment of ACE were asked regarding the
last visit to the biomedical health care facility. The ques-
tionnaire was forward- and back- translated into the local
language and piloted with local community members. The
English version of the questionnaire is available as an
Additional file (Additional file 1).
Statistical analysis
The questionnaires were entered into a mySQL database
(OracleCorp, Redwood Shores, CA, U.S.A) by a trained
data typist and the data analyzed using Stata 13 (StataCorp,
College Station, TX, U.S.A). Due to the non-normal
distribution of health care and traditional healer visits
and out-of-pocket costs (p < 0.0001 when performing
the Shapiro-Wilk test of normalcy), we report results as
median and interquartile range.
The annual cost of outpatient, out-of-pocket care was
calculated by multiplying the average cost per visit by
the average number of visits reported in the last 12-
months.
The time traveling to a traditional healer was not col-
lected in this study and only traditional healer fees are
reported as results.
Results
Household visits were made to all 311 individuals diag-
nosed with ACE in 2008; 20 were found to be deceased,
8 had permanently out-migrated from the study area, 9
refused to participate in the study and 24 were not avail-
able after visiting the household on at least 3 separate
occasions. There was no significant age or sex variation
between respondents and non-respondents. Of those alive
and found, 250 individuals (97 %) agreed to take part in
the study with a male-to-female ratio of 1.05. The median
age was 29 (inter-quartile range: 25th percentile- 75th per-
centile (IQR): 18–44 years). Seven (14 %) of those older
than 18 years were currently employed whilst 33 (50 %) of
those younger than 18 years were currently in school. One
hundred forty-eight individuals (59 %) were receiving an
epilepsy-related, government disability grant of $188 per
month, whilst 4 individuals (2 %) reported receiving
smaller non-epilepsy-related grant amounts ranging from
$44-176 (Table 1).
General health care utilization in people with epilepsy
Two hundred thirty-nine (96 %) individuals reported re-
ceiving non-epilepsy related health care when they last
needed it, which for 154 individuals (62 %) was in the
previous 30-days. For 231 (91 %) individuals, it was in the
last year. Four individuals (1 %) reported being denied
care and one participant cited inadequate levels of bio-
medical caregiver’s skill as reason for not receiving the
necessary health care. Six individuals did not report the
reason for not receiving care when they last needed it.
One hundred eighty-four (74 %) had ever sought
general care from both a biomedical facility (hospital,
health centre, or clinic) and a traditional healer, whilst
63 individuals (25 %) only sought general care from a
biomedical facility and 1 person sought general care
only from a traditional healer.
Epilepsy-related health care utilization
Within the last year, 132 people with epilepsy (53 %) re-
port consulting for epilepsy at a clinic, 162 (65 %) at a
hospital and 34 (14 %) with traditional healers. One
hundred sixty-eight individuals (67 %) reported previously
seeking epilepsy care from both a biomedical facility and a
traditional healer, whilst 61 individuals (24 %) have sought
care from only biomedical facilities. Eleven individuals
(4 %) reported only seeking care for epilepsy from trad-
itional healers, whilst 10 individuals sought no care- neither
from a biomedical facility nor a traditional healer. People
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with epilepsy sought general care at the government clinic
more frequently than epilepsy-related care (94 % versus
76 %), whilst utilizing hospital care at similar levels for
both epilepsy and general care (91 % versus 86 %)
(Table 2). The average number of hospital visits in the
previous 12-months was 4.06 (standard deviation (SD):
4.75) and average number of clinic visits was 6.5 (SD:
5.75).
Costs of biomedical health care utilization
The median cost per clinic visit was found to be $1.74
(IQR: $0-$4.80) (mean: 2.74; SD 3.74), whilst the median
cost per outpatient hospital visit was found to be $9.08
(IQR: $6.11-$12.91) (mean: 9.73; SD 5.34) – a statistically
significant difference (p < 0.001). The costs for epilepsy
care at clinic and hopsital can be found in Table 3. The
average annual cost for out-of-pocket, outpatient biomed-
ical care at a clinic or hospital was found to be $58.41.
The median travel and waiting time at the hospital
was twice that of the clinic (120 min/60 min and
240 min/120 min, respectively), whilst the time spent
with a health professional was the same (10 min) (Table 4).
The majority of respondents walked to the clinic but took a
public taxi to the hospital. During their last visit to the hos-
pital, 30 % of respondents saw a physician and 70 % saw a
nurse. During their last visit to the clinic, 11 % saw a phys-
ician and 89 % saw a nurse.
Costs of traditional healer utilization
During the last visit to a traditional healer 160 individ-
uals (87 %) had to pay for services, with payment in all
cases being cash. The median cost for a traditional healer’s
services was $52.36 ($34.90-$87.26). One individual re-
ported only having to pay the traditional healer if s/he was
cured of epilepsy.
Discussion
We found that the majority of people with ACE (91 %)
needed non-epilepsy care in the previous year, which was
similar to the 87 % percent in those greater than 50 years
old who reported needing care within the previous year in
a separate study within the same site [21]. Additionally,
53 % of people with ACE sought care for epilepsy from a
clinic and 65 % from a hospital in the previous year. One
limitation of the current study is that we have no indica-
tion as to whether the utilization of outpatient, biomedical
care was routine or the result of an epilepsy-related emer-
gency. Future investigation is warranted to address this.
Findings from high-income countries suggest that people
with epilepsy utilize health care more often than individuals
with other chronic conditions, including asthma, diabetes
and migraines [12, 13, 22]. People with epilepsy in the
Agincourt sub-district are required to visit the clinic once
per month to collect AEDs. This requirement may result in
the higher clinic utilization levels found in people with epi-
lepsy when compared to those greater than 50 years old
with other chronic conditions in the area [23]. Further work
to ascertain the reasons for increased health care utilization
and to determine whether people with epilepsy benefit from
















1st Quintile 31 (13)
2nd Quintile 65 (27)
3rd Quintile 50 (20)
4th Quintile 50 (20)
5th Quintile 49 (20)
Currently employed (if >18 years old)
Yes 14 (8)
No 169 (92)
Currently in school (if <18 years old)
Yes 33 (49)
No 34 (51)
aderived from 2009 Agincourt SES module; 5 missing data
Table 2 Lifetime utilization of care by people with epilepsy & median number of visits in previous year, Agincourt 2010–11 (n = 250)
Ever sought attention
for General care (%)
Median visits in previous
12-months (IQR)
Ever sought attention for
epilepsy-related care (%)
Median visits in previous
12-months (IQR)
Government Clinic 235 (94) 1 (0–5) 189 (76) 10 (0–11)
Government Hospital 228 (91) 0 (0–1) 216 (86) 2 (0–10)
Traditional Healer 185 (74) 0 (0–0) 179 (73) 0 (0–0)
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the care they seek in this rural southern African setting is
also warranted.
People with epilepsy were more likely to utilize public
clinics for non-epilepsy care, whilst more likely to utilize
public hospitals for epilepsy care. The frequency of the
visits to the clinic, for both general care and epilepsy-
related care, was greater than the frequency of hospital
visits. The reason for more people seeking care at the
hospital rather than the clinic is unclear. Perceived inad-
equacy of skilled manpower has been cited as a cause
for people not seeking care in a number of studies from
LMICs [24–26], and the perception of ‘more adequate’
manpower at the hospital (even though only 30 % of
patients saw a doctor at the hospital, compared to 11 % at
the clinic) could potentially explain a patient’s preference
to attend hospital for epilepsy care.
The non-availability of AEDs has also been shown to
affect care-seeking patterns [15] and is another possible
reason that some people with epilepsy chose to seek care
at the hospital rather than the clinic. Hospitals, with lar-
ger catchment areas, are likely to have a more continuous
supply of medication. In this study, 10 % of patients reported
that drugs are not always available and 22 % of patients
reported that the lack of drugs discouraged them from
utilizing the health facility. While this study didn’t ex-
plore the percentage of stock-outs at each facility, this
research does suggest that improving drug supply could
encourage better PHC facility attendance.
Traditional healer utilization
We found disclosed lifetime traditional healer usage to
be high in people with epilepsy for both epilepsy- and
non-epilepsy-related care (73 % and 74 %, respectively),
although the frequency of visits for both general and
epilepsy-related care was substantially less than visits to
both biomedical facilities within the 12 months preceding
this study. A national South African survey found similar
patterns, though lower utilization levels, and suggests that
poorer, rural, black populations utilize traditional healers
more than urban, non-black populations [27].
Utilization of traditional healers within the previous
12 months was low when compared to those who reported
ever seeking traditional healer care for epilepsy. It may be
that traditional healer care was sought during the initial
onset of seizures and care discontinued as the seizures
continued and traditional treatment proved ineffective.
Still, nearly 15 % of people with epilepsy reported at least
one visit to the traditional healer for epilepsy care within
the previous 12-months.
Our research concurs with findings that suggest the
costs associated with traditional healers are substantially
higher than costs of seeking care at biomedical facilities
[28]. The traditional healers’ costs we present only include
traditional healers’ fees and do not include time and
money spent traveling to and waiting to be seen by a
traditional healer, which would likely increase the total
costs. Our results likely represent the lower bound of
costs associated with traditional healer costs. The higher
cost per visit may be financially prohibitive and result in
the lower frequency of utilization. Furthermore, the aggre-
gate cost of traditional healers, taking into account the
lower frequency but higher per visit cost, may be similar
to the cost of biomedical facilities, which are utilized more
often, but cost, per visit, substantially less.
Understanding determinants of traditional healer
utilization in this context is warranted as the cultural un-
derstanding of epilepsy has been shown to be an import-
ant determinant in care-seeking behavior [29]. Identifying
ways of working with traditional healers to reduce the epi-
lepsy treatment gap, however, may be more productive
than attempting to change individual’s behavior.
Costs associated with epilepsy treatment
Seeking care at the hospital took significantly longer and
cost significantly more- more than twice the cost of
Table 3 Median direct costs for epilepsy care at clinic and
hospital, Agincourt 2010-11
Clinic Hospital
Direct Medical Costs (per visit)
Epilepsy Medication 0 (0–0) 0 (0–0)
Opening file $ 3.49 (3.49–5.24) $ 3.49 (3.49–3.49)
Direct Non-Medical Costs
(per visit)
Transportation $ 2.79 (1.74–4.89) $ 5.41 (4.19–7.68)
Food/drink purchased
due to visit
$ 3.49 (1.74–5.24) $ 4.36 (3.49–6.98)
Median (IQR)
Expressed in 2010 International dollars $
Table 4 Time associated with seeking epilepsy care (traveling,
waiting and consulting), Agincourt 2010–11
Travel Time Median Time
(in minutes)
IQR Mode of Transport
to Clinic 60 40–90 62 % walked, 38 % public taxi
to Hospital 120 120–240 92 % public taxi, 4 % walked,
3 % hired car, 1 % personal car
Waiting Time
to Clinic 120 10–420
to Hospital 240 30–600
Time with Health Professional Health Professional Seen
to Clinic 10 9–15 11 % physician, 89 % nurse





Wagner et al. BMC Health Services Research  (2016) 16:208 Page 5 of 8
seeking care at the clinic. As costs (including lost time)
associated with seeking epilepsy treatment have com-
monly been found to be associated with the epilepsy
treatment gap [15], increasing the utilization of care at
clinics by strengthening epilepsy care delivery will likely
reduce costs and potentially improve the treatment gap.
Furthermore, reducing transportation cost could result
in an overall reduction in out-of-pocket costs given that
transportation costs have been highlighted as a signifi-
cant cost in previous work in the area [28].
The overall annual out-of-pocket costs for out-patient
epilepsy care at biomedical facilities was found to be
$58.41, on average, yet this only represents a portion of
the total cost of epilepsy care in rural South Africa.
AED costs
Patients’AED costs are likely to be lower in South Africa
than other LMICs due to the free availability of AEDs at
health facilities. No patient reported paying for AEDs in
this study. In contrast, two other African studies found
AEDs to contribute 10 % [8] and 22 % [9] of the total
direct epilepsy treatment-related costs. One study from
rural Kenya found that people with epilepsy who had to
pay for AEDs were less likely to seek care [30], suggest-
ing that reducing or removing the cost of AEDs might
improve accessibility and consequently adherence [31].
Future work exploring adherence patterns in South Africa,
where AEDS are free, is warranted and could be a natural
experiment to establish whether free availability of AEDs
to patients truly does improve adherence.
Limitations
While this study presents previously unavailable informa-
tion on utilization patterns and out-of-pocket costs for
people with ACE in rural South Africa, there are a number
of potential limitations.
We only examined people with ACE in this study. We
recognize that this cohort does not represent all epilep-
sies and limits the interpretation of the results of this
study to people with ACE only. However, convulsive
epilepsies are often associated with the largest morbid-
ity, stigma and mortality [32] and potentially pose a
greater burden to individuals and families compared to
non-convulsive epilepsies.
This study did not measure indirect costs associated
with ACE, whilst a number of studies have found that
this cost can be significant- ranging from 12 % to 85 %
of the total annual costs due to epilepsy [7]. As such,
this study likely underestimates the total cost of ACE.
This study also only explored out-of-pocket, outpatient
costs associated with ACE and did not include costs as-
sociated with hospital admissions or epilepsy-related sur-
geries (in-patient costs). Studies from Italy have found
in-patient costs to be significant, especially in new-onset
epilepsy [33, 34]. This study only examined ACE, and
outpatient treatment patterns and costs for other types
of epilepsy may vary; however, further studies are needed
to verify this.
We chose an out-of-pocket costing approach for this
study. In countries, such as South Africa, with high
levels of unemployment and substantial inequality, using
the GDP per capita as a proxy for productivity may not
represent the actual productivity loss due to epilepsy
and, some argue, fails to account for the value of human
life [35, 36]. As such, a wider, societal costing approach
was not adopted in this study. Further development of
methodologies to allow for the accurate calculation of
productivity costs in areas of high unemployment where
formal sector employment is scarce is needed.
All costs and utilization analyzed in this study were
self-reported. Recall bias or intentional bias in reporting
may result in misreporting of costs and utilization asso-
ciated with seeking epilepsy care. Every effort, through
careful probing by well-trained fieldworkers, was made
to ensure the collection of accurate data.
Finally, this study only explored out-of-pocket costs of
epilepsy to the patient. Given the free availability of
AEDs in South Africa and the subsidized direct, medical
health care costs within the public healthcare system,
epilepsy-related treatment costs to the health care system
are potentially greater than in other African countries.
Conclusions
Out-of-pocket, direct, outpatient costs are likely to con-
tribute only a portion of the total economic burden of
epilepsy, with further research needed to determine in-
patient care costs as well as indirect costs attributable to
epilepsy in rural South Africa. However, this research
suggests that rural South African patients spend more
time and money seeking epilepsy care from a hospital than
from a clinic and readily seek both biomedical and trad-
itional healthcare. Interventions aimed at strengthening
epilepsy care at the primary care clinic, including regular
drug supply chains, and reducing the amount of time
spent traveling to and waiting to be seen at biomedical fa-
cilities could substantially reduce the out-of-pocket costs
experienced by people with active convulsive epilepsy.
Additional file
Additional file 1: Questionnaire used for data collection, Agincourt
2010. (DOCX 153 kb)
Abbreviations
$, International dollar; ACE, Active convulsive epilepsy; AEDs, Anti-epileptic
drugs; HDSS, Health and demographic surveillance system; IQR, interquartile
range; LMICs, Low- and middle- income countries; PHC, primary health care
Wagner et al. BMC Health Services Research  (2016) 16:208 Page 6 of 8
Acknowledgements
The authors wish to acknowledge Ms. Rachael Odhiambo for developing and
overseeing the study’s database as well as the fieldworkers of the MRC/Wits
Agincourt Research Unit involved in the Studies of the Epidemiology of
Epilepsy in Demographic Surveillance Systems (SEEDS) study and the Agincourt
sub-district population who took part in the study.
Funding
This study was funded through the Priority Cost-effective Lessons for Systems
Strengthening (PRICELESS) directorate, a sub-award through the University of
Washington from the Bill & Melinda Gates Foundation. The Agincourt HDSS is
funded by the Wellcome Trust, UK (grants 069683/Z/02/Z; 085477/Z/08/Z), with
important contributions from the University of the Witwatersrand, the South
African Medical Research Council, and National Institute on Aging (NIA) of
the National Institutes of Health (NIH). RGW is supported by the European
Union International Research Staff Exchange Scheme (grant no. 295168)
and CRN is funded by the Wellcome Trust, UK (083744).
Availability of data and materials
The data supporting the findings of this manuscript can be obtained on
request from the Agincourt HDSS data manager
(DataManager@agincourt.co.za) as part of the Studies of the Epidemiology of
Epilepsy in Demographic Surveillance Systems (Epidemiology and
Treatment of Epilepsy in sub-Saharan Africa) database. The questionnaire
used in this study can be found as an Additional file (Additional file 1) to this
manuscript.
Authors’ contributions
All authors participated in the conception the study and designed the data
collection tool. RGW, FXGO and ST oversaw the data collection. RGW
conducted the data analysis and interpretation with support from MYB, CRN
and LL. RGW wrote the first draft of the manuscript with significant support
from MYB, CRN, KH and LL. All authors read and approved the final version
of this manuscript.
Competing interests
The authors declare that they have no competing interests. MYB is a staff
member of the WHO. The author alone is responsible for the views expressed
in this publication and they do not necessarily represent the decisions, policy,
or views of the WHO.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Ethical clearance for the study was received from the Human Research
Ethics Committee at the University of the Witwatersrand, Johannesburg,
(Clearance number: M10566) and the Mpumalanga Provincial Research and
Ethics Committee. Written, informed consent was sought from each
participant in the study. Parental or guardian informed consent was sought
when the person with epilepsy was a child or individual with impaired
cognition. Verbal assent was also received from the child or individual with
impaired cognition.
Author details
1Studies of Epidemiology of Epilepsy in Demographic Surveillance Systems
(SEEDS) – INDEPTH Network, Accra, Ghana. 2MRC/Wits Rural Public Health &
Health Transitions Research Unit (Agincourt), School of Public Health, Faculty
of Health Sciences, University of the Witwatersrand, Johannesburg, South
Africa. 3Epidemiology and Public Health Sciences, Department of Public
Health and Clinical Medicine, Umeå University, Umeå, Sweden. 4World Health
Organization, Geneva, Switzerland. 5International Network for the
Demographic Evaluation of People and their Health (INDEPTH) Network,
Accra, Ghana. 6KEMRI/Wellcome Trust Research Programme, Centre for
Geographic Medicine Research – Coast, Kilifi, Kenya. 7Neurosciences Unit,
UCL Institute of Child Health, London, United Kingdom. 8Clinical Research
Unit, London School of Hygiene and Tropical Medicine, London, United
Kingdom. 9Department of Psychiatry, University of Oxford, Oxford, United
Kingdom. 10Priority Cost-effective Lessons for Systems Strengthening
(PRICELESS), Johannesburg, South Africa.
Received: 24 March 2015 Accepted: 13 June 2016
References
1. Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation
of the burden of active and life-time epilepsy: A meta-analytic approach.
Epilepsia. 2010;51:883–90.
2. World Health Organization. Epilepsy in the WHO African Region: Bridging
the Gap. Belhocine M, de Boer H, and Mandlhate C. Geneva: World Health
Organization; 2004.
3. Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton CR.
Incidence of epilepsy: a systematic review and meta-analysis. Neurology.
2011;77:1005–12.
4. Carpio A, Bharucha N, Jallon P, Beghi E, Campostrini R, Zorzetto S, Mounkoro P.
Mortality of epilepsy in developing countries. Epilepsia. 2005;46:28–32.
5. de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy.
Epilepsy Behav. 2008;12:540–6.
6. Begley CE, Annegers JF, Lairson DR, Reynolds TF. Estimating the cost of
epilepsy. Epilepsia. 1999;40 Suppl 8:8–13.
7. Strzelczyk A, Reese J, Dodel R, Hamer H. Cost of Epilepsy. Pharmacoeconomics.
2008;26:463–76.
8. Nsengiyumva G, Druet-Cabanac M, Nzisabira L, Preux PM, Vergnenègre A.
Economic Evaluation of Epilepsy in Kiremba (Burundi): A Case–Control
Study. Epilepsia. 2004;45:673–7.
9. Lagunju IA, Imam ZO, Adedokun BO. Cost of epilepsy in children attending
a tertiary centre in Nigeria. Int Health. 2011;3:213–8.
10. Begley CE, Beghi E. The economic cost of epilepsy: a review of the literature.
Epilepsia. 2002;43 Suppl 4:3–9.
11. Andersen RM. Revisiting the behavioral model and access to medical care:
does it matter? J Health Soc Behav. 1995;36:1–10.
12. Donker GA, Foets M, Spreeuwenberg P. Epilepsy patients: health status and
medical consumption. J Neurol. 1997;244:365–70.
13. Wiebe S, Bellhouse DR, Fallahay C, Eliasziw M. Burden of epilepsy: the Ontario
Health Survey. Can J Neurol Sci. 1999;26:263–70.
14. Meyer A-C, Dua T, Ma J, Saxena S, Birbeck G. Global disparities in the epilepsy
treatment gap: a systematic review. Bull World Health Organ. 2010;88:260–6.
15. Mbuba CK, Ngugi AK, Newton CR, Carter JA. The epilepsy treatment gap in
developing countries: a systematic review of the magnitude, causes, and
intervention strategies. Epilepsia. 2008;49:1491–503.
16. Kahn K, Collinson M, Gomez-Olive FX, Mokoena O, Twine R, Mee P, Afolbai SA,
Clark BD, Kabudula CW, Khosa A, Khoza S, Shabangu MG, Silaule B, Tibane JB,
Wagner RG, Gareen ML, Clark SJ, Tollman SM. Profile: Agincourt Health and
Socio-demographic Surveillance System. Int J Epidemiol. 2012;41:988–1001.
17. Collinson MA, Tollman SM, Kahn K. Migration, settlement change and health in
post-apartheid South Africa: triangulating health and demographic surveillance
with national census data. Scand J Public Health Suppl. 2007;69:77–84.
18. Cullinan K. Health Services in South Africa: A Basic Introduction. Health-e News
Services, January 2006. http://www.health-e.org.za/uploaded/
cb1f388f3b351708d915c12cfb4fc3cf.pdf.
19. Standard Treatment Guidelines and Essential Medicine List for South Africa
Primary Health Care. 5th ed. Pretoria South Africa: The National Department
of Health; 2014.
20. Wagner RG, Ngugi AK, Twine R, Bottomley C, Kamuyu G, Gómez-Olivé FX,
Connor MD, Collinson M a, Kahn K, Tollman S, Newton CR. Prevalence and Risk
Factors for Active Convulsive Epilepsy in rural northeast South Africa. Epilepsy
Res. 2014;108:782–91.
21. Ameh S, Gómez-Olivé FX, Kahn K, Tollman SM, Klipstein-Grobusch K.
Predictors of health care use by adults 50 years and over in a rural South
African setting. Glob Health Action. 2014;7:24771.
22. Reid AY, Metcalfe A, Patten SB, Wiebe S, Macrodimitris S, Jetté N. Epilepsy is
associated with unmet health care needs compared to the general population
despite higher health resource utilization-a Canadian population-based study.
Epilepsia. 2012;53:291–300.
23. Gomez-Olive F, Thorogood M, Clark B, Kahn K, Tollman S. Self-reported
health and health care use in an ageing population in the Agincourt
sub-district of rural South Africa. Glob Health Action. 2013;6:181–92.
24. Bassili A, Omar T, Zaki A. Pattern of diagnostic and therapeutic care of
childhood epilepsy in Alexandria, Egypt. Int J Qual Heal Care. 2002;14:277–84.
25. Debrock C, Preux PM, Houinato D, Druet-Cabanac M, Kassa F, Adjien C,
Avode G, Denis F, Boutros-Toni F, Dumas M. Estimation of the prevalence of
epilepsy in the Benin region of Zinvié using the capture-recapture method.
Int J Epidemiol. 2000;29:330.
Wagner et al. BMC Health Services Research  (2016) 16:208 Page 7 of 8
26. El SG, Newton C, Hartley S. Attitudes and practices of families and health
care personnel toward children with epilepsy in Kilifi Kenya. Epilepsy Behav.
2006;8:201–12.
27. Nxumalo N, Alaba O, Harris B, Chersich M, Goudge J. Utilization of traditional
healers in South Africa and costs to patients: findings from a national
household survey. J Public Health Policy. 2011;32 Suppl 1:S124–36.
28. Goudge J, Gilson L, Russell S, Gumede T, Mills A. The household costs of
health care in rural South Africa with free public primary care and hospital
exemptions for the poor. Trop Med Int Heal. 2009;14:458–67.
29. Kendall-Taylor N, Kathomi C, Rimba K, Newton CR. Traditional healers and
epilepsy treatment on the Kenyan coast. Epilepsia. 2008;49:1638–9.
30. Mbuba C, Ngugi AK, Fegan G, Ibinda F, Muchohi SN, Nyundo C,
Odhiambo R, Edwards T, Odermatt P, Carter JA, Newton CR. Risk factors
associated with the epilepsy treatment gap in Kilifi, Kenya:
a cross-sectional study. Lancet Neurol. 2012;11:688–96.
31. Cameron A, Bansal A, Dua T, Hill SR, Moshe SL, Mantel-Teeuwisse AK,
Saxena S. Mapping the availability, price, and affordability of antiepileptic
drugs in 46 countries. Epilepsia. 2012;53:962–9.
32. Lhatoo SD, Sander JW a S. Cause-specific mortality in epilepsy. Epilepsia.
2005;46 Suppl 1:36–9.
33. Beghi E, Garattini L, Ricci E, Cornago D, Parazzini F. Direct cost of medical
management of epilepsy among adults in Italy: a prospective cost-of-illness
study (EPICOS). Epilepsia. 2004;45:171–8.
34. Tetto A, Manzoni P, Millul A, Beghi E. The costs of epilepsy in Italy: a prospective
cost-of-illness study in referral patients with disease of different severity. Epilepsy
Res. 2002;48:207–16.
35. Begley C, Annegers J, Lairson D. Methodological issues in estimating the
cost of epilepsy. Epilepsy Res. 1999;33:39–55.
36. Liu J, Liu Z, Meng F. The economic burden of epilepsy in a sample of
people with epilepsy in China. Epilepsy Res. 2013;103:288–93.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wagner et al. BMC Health Services Research  (2016) 16:208 Page 8 of 8
